import
robust
infect
prevent
practic
highlight
recent
report
vancomycinresist
enterococci
vre
emerg
hospit
switzerland
australia
new
zealand
recent
australian
studi
shown
enterococci
faecium
microorgan
respons
variou
nosocomi
infect
behind
enterococc
bacteremia
case
survey
countri
found
ampicillinresist
strain
also
vancomycinresist
evid
suggest
e
faecium
strain
may
express
limit
resist
alcoholbas
sanitis
although
concentr
significantli
lower
recommend
use
hospit
set
continu
spread
antibiot
resist
area
signific
concern
necessit
care
consider
rigor
manag
practic
well
assess
altern
antisept
broad
hygien
applic
povidon
iodin
pvpi
widelyavail
altern
antisept
alcohol
commonli
use
clinic
set
includ
skin
disinfect
surgeri
usual
appli
skin
liquid
powder
use
treat
current
infect
prevent
spread
opportunist
pathogen
pvpi
broad
antimicrobi
spectrum
activ
plethora
virus
antibioticresist
bacteri
strain
tabl
suscept
gramneg
bacteria
includ
klebsiella
pneumonia
common
pathogen
hospit
suscept
gramposit
bacteria
includ
methicillinresist
staphylococcu
aureu
escherichia
coli
addit
pvpi
shown
superior
chlorhexidin
hand
wash
studi
compar
efficaci
bacteria
virus
tabl
pvpi
formul
first
becam
avail
activ
ingredi
list
world
health
organ
list
essenti
medicin
list
import
medicin
necessari
function
healthcar
system
pvpi
avail
counter
often
use
broadspectrum
topic
antisept
treatment
minor
cut
burn
abras
well
surgic
oper
theatr
widespread
use
divers
clinic
nonclin
set
recent
decad
made
numer
advantag
pvpi
formul
appar
addit
broadspectrum
effect
excel
safeti
profil
activ
iodin
variou
properti
aid
wound
heal
strong
evidencebas
rational
exist
applic
pvpi
treat
infect
wound
european
wound
manag
associ
publish
posit
paper
acknowledg
broad
spectrum
pvpi
activ
bacteria
virus
fungi
endospor
contrast
antisept
signific
resist
crossresist
observ
iodin
like
due
variou
mechan
iodin
elicit
effect
thu
found
divers
applic
healthcar
sterilis
agent
preand
postop
tabl
comparison
antimicrobi
activ
common
antisept
class
preclin
clinic
safeti
efficaci
data
show
pvpi
exhibit
characterist
wellsuit
woundheal
scenario
includ
efficaci
biofilm
good
toler
degre
antiinflammatori
effect
clinic
relev
heal
clean
wound
suppress
pvpi
support
wound
colonis
microorgan
particularli
use
treatment
sensit
wound
extend
durat
therapi
need
medic
gauz
wide
avail
make
formul
easier
appli
pvpi
also
elicit
potent
antivir
activ
commerci
avail
formul
shown
effect
term
viral
reduct
alcohol
nonalcohol
sanitis
well
antimicrobi
soap
alcohol
wide
use
antisept
like
due
afford
rel
eas
manufactur
shown
less
effect
pvpi
kill
microorgan
complianc
ethic
guidelin
articl
base
previous
conduct
studi
contain
studi
human
particip
anim
perform
author
refer
iodin
prepar
commonli
use
household
healthcar
set
consist
complex
povidon
hydrogen
iodid
element
iodin
target
structur
critic
surviv
replic
microorgan
common
formul
typic
consist
pvpi
solut
contain
avail
iodin
follow
applic
element
iodin
take
sever
form
aqueou
solut
molecular
hypoiod
acid
hoi
effect
term
antimicrobi
activ
iodin
molecul
free
oxidis
vital
pathogen
structur
amino
acid
nucleic
acid
membran
compon
equilibrium
achiev
circumst
pvpbound
iodin
releas
solut
replac
iodin
consum
germicid
activ
mainten
equilibrium
ensur
longlast
efficaci
bout
microorgan
prolifer
well
better
toler
patient
due
lower
level
irrit
electron
microscopi
biochem
observ
support
hypothesi
pvpi
disrupt
microbi
cell
wall
induc
pore
format
lead
cytosol
leakag
lack
report
resist
pvpi
date
thought
due
sheer
divers
suscept
target
within
pathogen
import
aspect
consid
face
rise
concern
antibiot
resist
emerg
antibiot
resist
strain
bacteria
includ
vre
methicillinresist
staphylococcu
aureu
mrsa
becom
signific
issu
healthcar
facil
throughout
world
inde
studi
shown
approxim
aureu
isol
europ
japan
harbour
gene
enabl
resist
quaternari
ammonium
compound
chlorhexidin
chlorhexidin
overus
thought
factor
emerg
resist
strain
gramneg
bacteria
preval
methicillin
resist
harbour
strain
aureu
capabl
caus
bloodstream
infect
earli
uk
rose
significantli
mean
overal
rate
bacteraemia
involv
mrsa
rang
per
occupi
bed
overus
antibiot
thought
contribut
factor
toward
rise
antibiot
resist
discourag
favour
wider
usag
antisept
difficult
bacteria
develop
resist
evid
crossresist
antisept
antibiot
document
mani
agent
centuri
use
signific
acquir
resist
crossresist
report
iodin
use
specif
indic
strike
lack
resist
thought
due
divers
mechan
iodin
simultan
exert
effect
although
aspect
remain
fulli
understood
iodin
microbicid
activ
known
involv
oxid
bacteri
cell
compon
includ
aminofatti
acid
nucleotid
lipid
cell
membran
enzym
cytosol
ultim
promot
denatur
deactiv
specif
multimod
action
iodin
known
aris
potent
oxid
nh
oh
shgroup
amino
acid
nucleotid
unsatur
fatti
acid
emerg
resist
like
prevent
sheer
divers
target
affect
effect
eventu
result
simultan
inactiv
bacteri
enzym
loss
genom
integr
cell
wall
damag
overwhelm
microorgan
repair
mechan
hallmark
studi
develop
bacteri
resist
iodin
investig
serial
passag
two
strain
pseudomona
aeruginosa
two
strain
escherichia
coli
two
strain
klebsiella
aerogen
one
strain
serratia
marcescen
presenc
suboptim
concentr
iodin
insuffici
caus
cell
death
investig
found
passag
detect
chang
observ
minim
inhibitori
concentr
iodin
need
time
taken
cell
death
occur
parent
strain
passag
subcultur
expos
efficaci
concentr
iodin
pvpi
formul
contain
avail
iodin
abl
kill
strain
test
min
cell
destroy
within
dilut
concentr
note
take
excess
min
achiev
effect
even
iodin
dilut
success
kill
strain
upon
prolong
exposur
realworld
scenario
overthecount
pvpi
formul
accommod
prolong
exposur
healthi
skin
commerci
formul
known
activ
h
compar
h
activ
document
chlorhexidin
fungi
endospor
particular
note
clinic
isol
chlorhexidineresist
klebsiella
pneumonia
also
crossresist
colistin
recent
identifi
chlorhexidin
commonli
use
disinfect
new
find
suggest
exposur
chlorhexidin
associ
stabl
resist
colistin
antibiot
last
resort
multidrugresist
infect
variou
experiment
model
develop
examin
antivir
properti
particular
agent
test
recommend
taken
stepwis
approach
european
committe
standard
cen
recommend
first
phase
involv
vitro
suspens
test
envelop
virus
repres
bulk
emerg
infecti
diseas
threat
phase
involv
similar
condit
nonenvelop
virus
third
final
phase
involv
human
hand
simul
studi
addit
virucid
hand
test
variat
latter
step
includ
quantit
nonpor
surfac
test
without
mechan
action
quantit
carrier
test
socal
test
involv
surfac
disinfect
mechan
action
fig
similarli
us
center
diseas
control
recommend
standardis
method
simul
hand
wash
antisept
formula
test
determin
efficaci
reduc
hand
microflora
new
test
model
enabl
assess
pvpi
formul
highli
infect
danger
pathogen
may
possibl
test
vivo
due
clinic
risk
ethic
consider
en
standardis
inactiv
assay
involv
viru
suspens
interf
substanc
bovin
serum
albumin
substanc
test
viru
control
mixtur
use
compar
effect
antivir
product
follow
specifi
contact
time
eg
virucid
activ
calcul
determin
differ
logarithm
titr
viru
control
test
viru
cultur
assess
microbicid
efficaci
challeng
due
difficulti
direct
observ
sheer
number
cell
particl
involv
consensu
within
medic
commun
settl
upon
minimum
measur
requir
evalu
microbicid
efficaci
refer
log
reduct
factor
mathemat
term
measur
titrat
endpoint
indic
reduct
number
live
viabl
microb
treatment
sanitis
disinfect
clean
european
standard
en
stipul
minimum
level
c
log
reduct
titr
virus
fungi
c
log
reduct
bacteria
repres
reduct
absolut
number
microb
respect
tabl
introduct
use
model
virus
significantli
aid
investig
new
antivirucid
agent
particularli
time
press
need
exampl
decemb
ebola
viru
first
discov
guinea
rapidli
becam
one
complex
epidem
recent
histori
due
high
biosecur
level
research
vaccin
contain
measur
viru
highli
limit
although
yet
confirm
surrog
ebola
viru
modifi
vaccinia
viru
mva
introduc
refer
claim
envelop
virus
hygien
hand
rub
hand
wash
model
allow
reason
progress
made
compar
antivir
agent
certain
set
similarli
middl
east
respiratori
syndrom
mer
first
discov
viru
infect
victim
countri
result
death
transmiss
known
frequent
occur
healthcar
set
highlight
need
suitabl
model
test
contain
measur
modifi
vaccinia
viru
ankara
use
test
model
mer
similar
structur
featur
cultiv
measur
influenza
viru
respons
signific
epidem
modern
world
annual
outbreak
result
approxim
million
case
sever
ill
death
per
year
influenza
studi
use
plaqu
inhibit
assay
show
pvpi
treatment
inhibit
infect
mdck
cell
human
eight
strain
avian
five
strain
influenza
virus
includ
receptor
bind
analysi
reveal
haemagglutinin
inhibit
like
caus
pvpi
virucid
activ
rather
inhibit
hostspecif
sialic
acid
receptor
find
also
demonstr
two
specif
mechan
reduct
viral
growth
name
pvpi
blockad
viral
attach
host
cell
receptor
inhibit
viral
releas
infect
cell
pvpi
formul
also
known
broad
antivir
properti
effect
mechanist
similar
principl
iodin
antibacteri
activ
exampl
virucid
mechan
action
pvpi
determin
involv
inhibit
essenti
viral
enzym
neuraminidas
inactiv
enzym
block
viral
releas
host
cell
prevent
spread
viru
uninfect
cell
addit
pvpi
also
inhibit
viral
haemagglutinin
result
blockad
attach
host
cell
receptor
simultan
target
critic
aspect
viral
machineri
need
replic
pvpi
reduc
likelihood
resist
emerg
sudden
mutat
guidelin
pvpi
formul
shown
elicit
viral
inactiv
test
system
use
modifi
vaccinia
viru
virucid
efficaci
case
determin
occur
within
contact
follow
hand
simul
studi
murin
noroviru
found
hand
wash
pvpi
effect
chlorhexidin
soft
soap
gold
standard
recommend
pvpi
also
shown
virucid
enteroviru
coxsackieviru
compar
disinfect
need
develop
potent
antivir
formul
suitabl
widespread
use
brought
promin
emerg
rapid
viral
outbreak
past
decad
mani
coronavirus
middl
east
respiratori
syndrom
coronaviru
merscov
singlestrand
rna
viru
first
identifi
outbreak
eventu
spread
countri
worldwid
trigger
mass
media
coverag
date
viru
remain
categoris
high
biosafeti
risk
contain
remain
primari
measur
combat
outbreak
vaccin
specif
antivir
treatment
yet
develop
howev
randomis
control
clinic
trial
shown
pvpi
alcoholbas
hand
rub
effect
soapbas
hand
wash
hand
hygien
presenc
transmiss
virus
studi
evalu
mouthwash
surgic
scrub
skin
cleanser
formul
pvpi
antivir
activ
mer
coronaviru
shown
viral
titr
could
reduc
factor
log
correspond
inactiv
level
remark
level
potenc
achiev
within
applic
pvpi
formul
includ
pvpi
surgic
scrub
pvpi
garglemouthwash
pvpi
skin
cleanser
formul
brand
name
betadin
mundipharma
limburg
germani
find
indic
pvpibas
hand
hygien
product
use
decontamin
virallyinfect
skin
pvpi
mouthwash
reduc
viral
load
oral
caviti
oropharynx
potenti
aid
support
hygien
measur
need
reduc
sever
futur
mer
outbreak
earlier
cooper
studi
present
result
comparison
antisept
shown
pvpi
impact
infect
signific
human
pathogen
virus
includ
polio
adeno
rota
mump
rhino
coxsacki
rubella
herp
measl
influenza
virus
mump
adenovirus
decim
test
set
reduct
within
exposur
pvpi
concentr
higher
influenza
viru
inactiv
reduct
follow
dose
level
hiv
reduc
reduct
exposur
dose
higher
howev
coxsackieviru
polioviru
type
observ
sensit
pvpi
inactiv
virus
requir
dose
higher
inactiv
case
rhinoviru
author
conclud
pvpi
prepar
effect
measl
mump
herp
hiv
influenza
rotavirus
rubella
polio
adeno
rhinovirus
sensit
higher
dose
fact
viru
type
could
either
sensit
resist
regardless
whether
envelop
nonenvelop
suggest
mechan
specif
certain
viral
type
like
extent
influenc
iodin
sensit
overal
find
particular
relev
given
overwhelm
proport
sore
throat
case
thought
viral
origin
appear
remain
overprescrib
antibiot
case
hospit
set
particularli
challeng
antisepsi
antibioticresist
strain
constant
threat
pvpi
wide
use
surgic
set
prevent
infect
ensur
preoper
decontamin
aim
decontamin
reduc
risk
skin
flora
introduc
sensit
area
skin
barrier
breach
normal
innocu
bacteri
flora
usual
colonis
healthi
skin
becom
harm
set
particularli
immunocompromis
individu
pvpi
surgic
scrub
deterg
foam
booster
recommend
effect
preoper
sterilis
comprehens
literatur
review
joint
committe
consist
repres
british
societi
antimicrobi
chemotherapi
hospit
infect
societi
infect
control
nurs
associ
conclud
povidon
iodin
triclosan
help
erad
suppress
skin
colonis
short
period
particularli
preoper
set
work
parti
recommend
find
patient
bath
daili
day
appropri
antisept
deterg
skin
moisten
antisept
deterg
appli
thoroughli
area
rins
bath
shower
use
antisept
also
recommend
wash
procedur
bed
bath
patient
requir
endotrach
intub
higher
risk
microbi
infect
bacteri
strain
includ
nosocomi
pneumonia
studi
hospit
patient
undergo
oral
intub
found
gargl
ml
mgml
pvpi
min
twice
reduc
presenc
bacteria
trachea
prior
intub
patient
control
group
mrsa
gargl
tap
water
found
bacteria
contamin
tip
tracheal
tube
upon
remov
howev
group
gargl
pvpi
gener
bacteria
mrsa
erad
pharynx
prior
intub
well
tip
tracheal
tube
remov
proper
use
pvpi
surgic
site
effect
decontamin
risk
postop
infect
greatli
reduc
inde
postop
infect
rate
lower
procedur
includ
sterilis
step
pvpi
patient
undergo
gastrointestin
procedur
higher
risk
postop
wound
infect
due
difficulti
remov
enter
bacteria
present
gut
howev
pvpi
formul
also
shown
effect
prevent
complic
aris
infect
set
result
averag
five
fewer
day
spent
hospit
recoveri
addit
use
pvpi
mouthwash
prior
dental
extract
procedur
shown
reduc
gingiv
bacteria
lower
risk
bacteraemia
sterilis
approach
consid
use
combin
pvpi
microbi
pathogen
influenza
tuberculosi
spread
airborn
pathway
hospit
set
although
uvc
light
known
inactiv
agent
even
brief
exposur
highli
energet
light
damag
human
tissu
interest
recent
studi
research
use
uvbas
sterilis
approach
incorpor
singlewavelength
faruvc
light
gener
filter
excilamp
found
kill
pathogen
microorgan
importantli
wavelength
use
penetr
human
skin
eye
tissu
power
enough
caus
biolog
damag
mammalian
cell
due
consider
smaller
scale
microbi
structur
exist
faruvc
light
highli
effect
inactiv
strain
influenza
viru
viral
particl
suspend
aerosolis
droplet
simul
gener
human
cough
breath
addit
afford
antisept
approach
one
major
advantag
uvc
light
like
effect
airborn
microb
like
pvpi
broad
spectrum
effect
particularli
import
consid
multidrugresist
variant
bacteria
emerg
set
long
known
hand
wash
perform
properli
significantli
reduc
carriag
spread
pathogen
direct
effect
reduc
patient
morbid
mortal
nosocomi
infect
hand
wash
import
establish
procedur
infect
control
clinicallyvalid
efficaci
core
compon
protocol
aim
reduc
infecti
outbreak
skin
act
reservoir
infecti
agent
use
pvpi
hand
disinfect
repres
altern
alcoholbas
hand
rub
medic
soap
contain
pvpi
readili
avail
pvpi
soap
shown
equival
superior
efficaci
alcoholbas
hand
sanitis
test
noroviru
common
caus
gastroenter
contrast
chlorhexidin
triclosanbas
hand
wash
shown
inferior
noroviru
practic
applic
test
hand
wash
pvpibas
formul
shown
similar
antimicrobi
efficaci
alcoholbas
hand
rub
prefer
use
soap
water
alon
direct
comparison
virucid
activ
variou
hand
sanitis
includ
antimicrobi
soap
alcoholbas
sanitis
found
modifi
fingerpad
test
soap
contain
pvpi
superior
soap
sanitis
test
three
sanitis
test
studi
includ
ethanol
phosphor
acid
triclosan
chlorhexidin
formul
modifi
test
follow
en
standard
show
soap
contain
pvpi
abl
inactiv
murin
noroviru
approxim
log
step
recent
handhygien
simul
studi
describ
test
compar
efficaci
differ
agent
hand
antisepsi
one
studi
volunt
prewash
hand
artifici
contamin
either
escherichia
coli
bactericid
test
murin
noroviru
virucid
antisepsi
agent
use
randomis
approach
number
test
organ
releas
fingertip
calcul
term
mean
log
reduct
factor
per
guidelin
direct
comparison
pvpi
chlorhexidin
formul
show
clear
superior
pvpi
murin
noroviru
pvpi
chlorhexidin
significantli
better
soft
soap
e
coli
experiment
model
could
help
broader
assess
antisepsi
agent
associ
profession
infect
control
epidemiolog
apic
publish
seri
guidelin
hand
wash
hand
antisepsi
healthcar
set
supplement
written
variou
hygien
author
includ
us
food
drug
administr
guidelin
recommend
formul
contain
iodin
use
surgic
hand
scrub
lower
concentr
good
antimicrobi
activ
due
concentr
free
iodin
increas
extent
solut
dilut
thorough
hand
antisepsi
achiev
hand
wash
surgic
scrub
antimicrobi
agent
recommend
surgic
set
perform
invas
procedur
placement
intravascular
cathet
scenario
deem
necessari
reduc
number
resid
skin
flora
transient
microorgan
skin
recent
hospit
report
vancomycinresist
e
faecium
emerg
well
alcohol
toler
strain
may
advis
take
new
consider
account
case
infecti
enterococci
identifi
independ
vancomycin
resist
hand
disinfect
almost
certainli
recommend
case
e
faecium
confirm
extent
hand
disinfect
use
context
avail
activ
substanc
consid
disinfect
list
disinfect
commiss
associ
appli
hygien
vah
also
mention
product
variou
activ
ingredi
includ
npropanol
peroxid
iodin
product
combin
quaternari
compound
phenol
deriv
guanidin
deriv
iodinecleav
compound
also
consid
surfac
disinfect
approach
reli
sole
alcohol
disinfect
avoid
replac
combin
approach
alcohol
activ
substanc
final
disinfect
patient
room
e
faecium
may
present
per
compoundbas
prepar
use
pvpi
scrub
better
skin
toler
soap
formul
chlorhexidin
quaternari
ammonium
compound
although
urgent
need
welldesign
studi
directli
compar
clinic
econom
profil
antisept
set
pvpi
consid
antisept
choic
manag
superfici
skin
infect
mouthwash
gargl
commonli
use
hospit
set
prevent
respiratori
endotrach
infect
one
hospitalbas
trial
adult
subject
chronic
respiratori
diseas
repeat
infect
gargl
pvpi
formul
multipl
time
daili
extend
durat
year
prior
initi
studi
patient
experienc
total
episod
infect
mean
episod
reduc
remark
mean
number
follow
pvpi
gargl
repres
reduct
number
episod
common
caus
strain
identifi
h
influenza
catarrhali
pneumococci
influenza
mrsa
reduc
similarli
test
pvpi
garglemouthwash
dilut
reflect
reallif
scenario
dilut
equival
concentr
pvpi
accord
standard
show
rapid
antimicrobi
effect
exposur
effect
clinicallymeaning
bactericid
activ
klebsiella
pneumonia
streptococcu
pneumonia
observ
condit
well
inactiv
common
agent
seriou
respiratori
tract
infect
includ
sarscov
merscov
influenza
viru
rotaviru
seek
investig
efficaci
pvpi
gargl
nonhospit
set
studi
pvpi
chlorhexidin
glucon
chg
cetylpiridium
chlorid
cpc
gargl
conduct
support
pvpi
studi
across
eight
middl
school
japan
pvpi
show
highest
bactericid
rate
test
strain
observ
within
exposur
middl
school
student
train
encourag
use
gargl
comparison
absente
made
school
encourag
practic
middl
school
use
pvpi
gargl
absente
due
common
cold
influenza
significantli
lower
compar
school
use
two
agent
author
conclud
use
pvpi
gargl
result
decreas
absente
due
cold
influenza
infect
year
sinc
pvpi
first
market
antibioticantisept
agent
sinc
introduct
variou
agent
includ
triclosan
carbapenem
introduc
although
year
sinc
new
class
antibiot
last
discov
accord
recent
review
confirm
report
resist
pvpi
date
numer
studi
shown
pvpi
broader
antimicrobi
spectrum
avail
antisept
includ
chloroxylenol
chlorhexidin
quaternari
ammonium
compound
although
alcoholbas
antisept
also
broad
potenc
unlik
pvpi
formul
typic
effect
fungal
bacteri
spore
interestingli
honey
maggot
shown
antibacteri
properti
appli
therapeut
woundtreat
set
although
potenc
comparison
iodin
virus
endospor
remain
determin
pvpi
well
toler
major
patient
particularli
appli
skin
comparison
chlorhexidin
exampl
pvpi
rare
associ
allerg
contact
dermat
urticari
anaphylact
reaction
exceedingli
rare
eu
safeti
assess
report
find
assess
human
data
involv
g
pvpi
appli
hand
forearm
contact
time
less
min
conclud
propos
use
iodin
hand
disinfect
product
suitabl
human
health
although
pvpi
gener
seen
safe
longterm
use
case
thyroid
dysfunct
induc
pvpi
report
reason
patient
receiv
pvpi
treatment
extend
period
time
care
monitor
recent
report
emerg
resist
antibiot
includ
ampicillin
vancomycin
attent
turn
use
broadspectrum
antisept
limit
hospitalbas
infecti
outbreak
despit
long
histori
efficaci
use
signific
case
resist
iodin
emerg
thought
due
broad
antimicrobi
activ
confirm
global
health
author
includ
world
health
organ
european
wound
manag
associ
european
guidelin
test
pvpi
formul
hand
wash
topic
applic
recommend
stepwis
approach
combin
standardis
test
use
valid
test
model
formul
like
betadin
antisept
solut
demonstr
activ
envelop
nonenvelop
virus
includ
ebola
mer
sar
coronaviru
influenza
hfmd
virus
enteroviru
coxsackieviru
potenc
access
pvpi
formul
therefor
like
continu
signific
benefit
human
health
global
scale
particularli
develop
world
ensur
afford
access
reliabl
antisept
agent
challeng
furthermor
comparison
antibiot
use
broadspectrum
antisept
reduc
likelihood
resist
emerg
due
multipl
mechan
action
target
divers
aspect
cell
biolog
replic
machineri
contrast
pvpi
bacteri
resist
chlorhexidin
quaternari
ammonium
salt
silver
triclosan
document
long
track
record
efficaci
use
pvpi
clinic
set
also
advantag
clinic
investig
recommend
decisionmak
guid
avail
scientif
evid
regard
expect
benefit
risk
therapeut
applic
reason
consider
unmet
medic
need
still
remain
infecti
diseas
home
healthcar
environ
call
investig
pvpi
formul
set
